胃泌素抑制肽(GIP)重組蛋白
Recombinant Gastric Inhibitory Polypeptide (GIP)
Incretin hormone; Glucose Dependent Insulinotropic Peptide
- 編號URPA882Ra01
- 物種Rattus norvegicus (Rat，大鼠) 相同的名稱，不同的物種。
- 來源原核表達
- 宿主E.coli
- 內毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位分泌
- 預測分子量42.9kDa
- 實際分子量43kDa(差異分析請參閱說明書)
- 片段與標簽Leu11~Leu124 with N-terminal His and GST Tag
- 緩沖液成份20mM Tris, 150mM NaCl緩沖液（pH8.0, 含有1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose和Proclin300）
- 性狀凍干粉
- 純度> 95%
- 等電點6.5
-
應用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 456 ¥ 1140 ¥ 2280 ¥ 6840 ¥ 17100
- 欲了解實際交易價格和更多情況，請與當地經銷商聯系!
-
產品包裝(模擬)
-
產品包裝(模擬)
-
SDS-PAGE圖
-
通過ISO 9001、ISO 13485質量體系認證
序列
用法
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產生。保質期內，在適當的條件下存儲，損失率低于5%。
增值服務
相關產品
| 編號 | 適用物種：Rattus norvegicus (Rat，大鼠) | 應用(僅供研究使用，不用于臨床診斷！) |
| URPA882Ra01 | 胃泌素抑制肽(GIP)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UCPA882Ra11 | 胃泌素抑制肽(GIP)牛血清白蛋白偶聯物 | Immunogen; SDS-PAGE; WB. |
| UCPA882Ra21 | 胃泌素抑制肽(GIP)卵白蛋白偶聯物 | Immunogen; SDS-PAGE; WB. |
| UPAA882Ra08 | 胃泌素抑制肽(GIP)多克隆抗體 | WB; IHC; ICC; IP. |
| UPAA882Ra01 | 胃泌素抑制肽(GIP)多克隆抗體 | Testing in progress |
| UMAA882Ra21 | 胃泌素抑制肽(GIP)單克隆抗體 | WB; IHC; ICC; IP. |
| UMEA882Ra | 胃泌素抑制肽(GIP)檢測試劑盒(酶聯免疫吸附試驗法,小樣本) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| UCEA882Ra | 胃泌素抑制肽(GIP)檢測試劑盒(酶聯免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA882Ra | 胃泌素抑制肽(GIP)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UKSA882Ra11 | 胃泌素抑制肽(GIP)檢測試劑盒DIY材料(酶聯免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻
| 雜志 | 參考文獻 |
| Scientific Reports | The?anti-hyperglycemic?efficacy?of a?lipid-lowering?drug?Daming?capsule?and the?underlyingsignaling?mechanisms?in a?rat?model?of?diabetes?mellitus. [pubmed:27721485] |
| Obesity surgery | The Effects of Duodenojejunal Omega Switch in Combination with High-Fat Diet and Control Diet on Incretins, Body Weight, and Glucose Tolerance in Sprague-Dawley Rats. [pubmed:28840471] |
| Obesity?Surgery? | Preserving Duodenal-Jejunal (Foregut) Transit Does Not Impair Glucose Tolerance and Diabetes Remission Following Gastric Bypass in Type 2 Diabetes Sprague?… [Pubmed:29098544] |
| BioMed Research International | Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity [] |
| Diabetes Research and Clinical Practice | Low AS160 and high SGK basal phosphorylation associates with impaired incretin profile and type 2 diabetes in adipose tissue of obese patients [Pubmed: 31734225] |
| OBESITY SURGERY | The Leading Role of Peptide Tyrosine Tyrosine in Glycemic Control After Roux-en-Y Gastric Bypass in Rats [Pubmed: 31701411] |
| FUTURE SCIENCE | Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes [Pubmed:35251693] |
留言咨詢
